The FDA announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches. The RFI seeks comments, data, and information on specific protocol elements relevant to ibogaine drug development, including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules and safety oversight. The FDA is seeking comments, data, and information in four primary areas: general study design; dose selection and escalation; safety considerations; ethical and oversight considerations. The public will have 45 days following publication in the Federal Register to submit comments, data or information to the docket.





